Literature DB >> 17569897

Rosiglitazone and implications for pharmacovigilance.

Dhruv Kazi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17569897      PMCID： PMC1892466          DOI： 10.1136/bmj.39245.502546.BE

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

Review 1.  Lessons from the glitazones: a story of drug development.

Authors:  E A Gale
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

2.  Protecting the health of the public--Institute of Medicine recommendations on drug safety.

Authors:  Bruce M Psaty; Sheila P Burke
Journal:  N Engl J Med       Date:  2006-10-09       Impact factor: 91.245

3.  The record on rosiglitazone and the risk of myocardial infarction.

Authors:  Bruce M Psaty; Curt D Furberg
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

4.  Rosiglitazone and cardiotoxicity--weighing the evidence.

Authors:  David M Nathan
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

Review 5.  Meta-analysis and its problems.

Authors:  H J Eysenck
Journal:  BMJ       Date:  1994-09-24

6.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Authors:  Steven E Nissen; Kathy Wolski; Eric J Topol
Journal:  JAMA       Date:  2005-10-20       Impact factor: 56.272

7.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Ramón Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

8.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245
  8 in total
  4 in total

1.  Pharmacovigilance in developing countries.

Authors:  Munir Pirmohamed; Kwame N Atuah; Alex N O Dodoo; Peter Winstanley
Journal:  BMJ       Date:  2007-09-08

2.  Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Authors:  Anthony Grosso; Ian Douglas; Aroon Hingorani; Raymond MacAllister; Liam Smeeth
Journal:  Br J Clin Pharmacol       Date:  2008-07-31       Impact factor: 4.335

3.  How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Authors:  Jason C Hsu; Dennis Ross-Degnan; Anita K Wagner; Fang Zhang; Christine Y Lu
Journal:  Clin Ther       Date:  2015-05-11       Impact factor: 3.393

4.  Use of the self-controlled case series method in drug safety assessment.

Authors:  Anthony Grosso; Ian Douglas; Raymond MacAllister; Irene Petersen; Liam Smeeth; Aroon D Hingorani
Journal:  Expert Opin Drug Saf       Date:  2011-03-15       Impact factor: 4.250
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.